A ranar 31 ga Yuli, AstraZeneca da Merck & Co. sun sanar da cewa an amince da maganin hana PARP Lynparza, tare da Abiraterone da prednisolone, a China don maganin manya marasa lafiya da ke fama da cutar kansar mafitsara mai jure wa castration (mCRPC) waɗanda ke ɗauke da maye gurbi na germline ko somatic BRCA (gBRCAm ko sBRCAm).
A halin yanzu, har yanzu akwai gwaje-gwaje da yawa na asibiti na sabbin fasahohin yaƙi da cutar kansa a China waɗanda ke neman marasa lafiya. Tuntuɓi kan sabbin magunguna da fasahohi, zaku iya tuntuɓar Sashen Ƙasa da Ƙasa na Asibitin Oncology na Yankin Kudu na Beijing.
Lambar Waya: 4008803716
Shaidar WeChat: 17801183037
Imel:myimmnet@163.com
Lynparza (olaparib) magani ne na farko da ke hana cutar PARP kuma magani ne na farko da aka yi niyya don toshe martanin lalacewar DNA (DDR) a cikin ƙwayoyin cuta/ƙarancin da ke ɗauke da ƙarancin HRR, kamar maye gurbi a cikin BRCA1 da/ko BRCA2. Hana PARP tare da Lynparza yana haifar da kama PARP da aka ɗaure zuwa karyewar DNA mai igiya ɗaya, dakatar da kwafi na cokula, rugujewarsu da kuma samar da karyewar DNA mai igiya biyu da mutuwar ƙwayoyin cutar kansa.
Wannan amincewar ta dogara ne akan sakamakon binciken ƙananan ƙungiyoyi daga ƙungiyoyin duniya da na China na gwajin PROpel Phase III. PROpel gwaji ne na asibiti na Phase III wanda bazuwar, makanta biyu, wanda ke kimanta inganci, aminci, da juriya na Lynparza tare da Abiraterone da prednisolone idan aka kwatanta da placebo da Abiraterone da prednisolone a cikin marasa lafiya maza da ke fama da mCRPC waɗanda ba su taɓa shan maganin chemotherapy ko sabon maganin hormonal ba (NHA) a matakin mCRPC.
Bayanai daga ƙungiyar marasa lafiya ta duniya da ke fama da maye gurbi na BRCA sun nuna cewa Lynparza tare da Abiraterone sun nuna ci gaba mai mahimmanci a asibiti a cikin tsira ba tare da ci gaba da rediyo ba (rPFS) idan aka kwatanta da maganin Abiraterone monotherapy. Binciken ƙananan rukuni na marasa lafiya da ke fama da maye gurbi na BRCA a cikin ƙungiyar duniya ya nuna cewa Lynparza tare da Abiraterone sun rage haɗarin ci gaban cuta ko mutuwa da kashi 76% da haɗarin mutuwa da kashi 70%. Matsakaicin rPFS da matsakaicin rayuwa gaba ɗaya (OS) a cikin ƙungiyar Lynparza da Abiraterone ba a kai ga cimma su ba tukuna, yayin da matsakaicin rPFS da matsakaicin OS a cikin ƙungiyar Abiraterone monotherapy sune watanni 8 da watanni 23, bi da bi.
A halin yanzu, har yanzu akwai gwaje-gwaje da yawa na asibiti na sabbin fasahohin yaƙi da cutar kansa a China waɗanda ke neman marasa lafiya. Tuntuɓi kan sabbin magunguna da fasahohi, zaku iya tuntuɓar Sashen Ƙasa da Ƙasa na Asibitin Oncology na Yankin Kudu na Beijing.
Lambar Waya: 4008803716
Shaidar WeChat: 17801183037
Email：myimmnet@163.com
Lokacin Saƙo: Agusta-07-2025